Imunon 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Imunon reported 3rd quarter 2026 research and development expenses of $1.8 million, compared with $1.9 million in the same period last year, and general and administrative expenses of $1.7 million, compared with $1.6 million.
- Non-operating expenses were $302,000, net loss available to common shareholders was $3.8 million, or $0.64 a share, and net cash used in operating activities was $3.2 million for the quarter.
- For the 9 months ended September 30th, 2026, net cash used in operating activities was $10.2 million; at September 30th, 2026, cash and cash equivalents were $4.0 million and restricted cash was $5.0 million.
- The company reported substantial doubt about its ability to continue as a going concern, and its independent registered public accounting firm included a going concern explanatory paragraph in its report.
- OVATION-3 is a randomized 1-to-1, approximately 500-patient Phase 3 trial evaluating intraperitoneal Imunon-001 at 100 milligrams per meter squared with standard of care neoadjuvant and adjuvant chemotherapy in newly diagnosed advanced epithelial ovarian cancer; overall survival is the primary endpoint.
- At the end of the quarter, OVATION-3 had 18 sites selected, with 9 active and 9 in startup; average enrollment across active sites was approximately 0.4 patients per site per month, compared with a planning assumption of approximately 0.3.
- In the 26-patient intent-to-treat cohort of the Phase 2 MRD study, median recurrence-free survival was 26.1 months in the Imunon-001 arm versus 11.4 months in the control arm; the log-rank p-value was 0.17, and management described the findings as hypothesis-generating, not confirmatory.
- Among patients reaching the MRD study's primary assessment at second-look laparoscopy, MRD positivity was 44.4% versus 66.7%, clearance of circulating tumor DNA was 87.5% versus 62.5%, and no evidence of disease following frontline therapy was 100% versus 56% for Imunon-001 and control, respectively.
- Management cited OVATION-2 results showing median survival of 45.1 months versus 30.4 months, and median survival of 65.6 versus 41.4 months among patients who received PARP inhibitor maintenance; the 14.7-month overall survival difference had a 95% confidence interval of -3.8 to 33.3 months and a one-sided p-value of 0.06.
- The independent Data and Safety Monitoring Committee recommended that the MRD study continue without modification, and recent independent data monitoring committee reviews identified no new safety concerns in OVATION-3; across the studies discussed, management reported no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events.
- Imunon entered a CRADA with the National Cancer Institute's Cancer Therapy Evaluation Program, under which National Cancer Institute investigators will evaluate Imunon-001 in additional solid tumor indications and combined regimens, with the National Cancer Institute assuming regulatory sponsorship and operational responsibility for conducting the studies.
- Imunon agreed to sell its rights to ThermoDox to VasilDox Therapeutics, contingent on VasilDox completing a planned $2.5 million financing; upon closing, Imunon would receive an equity interest of approximately 4.76%, potential milestone payments of up to $16.5 million, and tiered royalties ranging from 3.5% to 6% on net sales of ThermoDox-related products if approved.
- In late September, Imunon exchanged $1.2 million of outstanding debt plus accrued interest for non-convertible preferred stock, reducing the balance of that note by approximately 43% without issuing common stock or warrants.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to Imunon's third quarter 2026 financial results and business update conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star, then the number 1 on your telephone keypad. To withdraw your question, press star one again. I would now like to turn the conference over to Valter Pinto, Managing Director at KCSA Strategic Communications, for introductions.
Please go ahead. Thank you, operator, and good morning.
Welcome to the Imunon third quarter 2026 financial results and business update conference call. Joining us today are Dr. Stacy Lindborg, President and Chief Executive Officer, Dr. Douglas Faller, Executive Vice President and Chief Medical Officer, and Josh Blacher, Interim Chief Financial Officer. Michael Tardugno, Executive Chairman, is also available for the question-and-answer portion of today's call. Before we begin, I'd like to remind everyone that our remarks today include forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, the potential of the company's therapies to address unmet medical needs, the market potential for its product candidates if approved, and the company's plans and expectations for its development programs.
Words such as may, will, expect, plan, anticipate, estimate, and intend identify these forward-looking statements. Actual results may differ materially from those projected. Additional information on the factors that could cause actual results to differ is detailed in Imunon's filings with the Securities and Exchange Commission, which are available at sec.gov and on the company's website. The forward-looking statements made on this call speak only as of today's date, and the company undertakes no obligation to update them except as required by law. With that, I'd now like to turn the call over to Dr. Stacy Lindborg, President and Chief Executive Officer.
Stacy? Thank you, Walter, and good morning, everyone.
Thank you for joining us today and for your continued support of Imunon. On our second quarter call in August, I said our priorities were clear: execute our phase III OVATION 3 study, generate high-quality data, and deliver a much-needed therapy option for women with advanced ovarian cancer. The third quarter was a period in which we advanced all three: continued OVATION 3 enrollment, additional external validation of the data, and further portfolio and capital structure actions. We recently hosted our 2026 R&D Day in New York City, where clinical investigators presented the full case for the phase III IMNN-001 study in frontline ovarian cancer, which included the final phase II overall survival results, the preliminary minimal residual disease findings, and the path to a confirmatory readout in OVATION 3.
Our North Star remains unchanged: bring a much-needed treatment option to women with advanced ovarian cancer, a disease that affects approximately 300,000 women worldwide each year, has five-year survival rates of approximately 41% for women diagnosed at stage III and approximately 20% for women diagnosed at stage IV, and has seen little advancement in frontline care, standard of care, for well over two decades. Before discussing our clinical progress, I would like to highlight the three themes that shaped the quarter. First, independent validation of IMNN-001 from the National Cancer Institute, from an independent data monitoring committee, and from the investigators who presented at our R&D Day. Second, continued enrollment momentum in our pivotal phase III study, OVATION 3, now with a clearly defined path to two pre-planned interim analyses.
Third, the steps we have taken to sharpen the portfolio and strengthen the balance sheet so that every dollar and every person is pointed at OVATION 3. Let me start with our R&D Day, because it brought the entire investment case together in one place. On September 23rd in New York, we set out to answer three questions: why systemic IL-12 failed historically, why IMNN-001 is different, and why the next stretch of OVATION 3 is the value-defining chapter of this program. We did not answer these questions alone. Dr. Premal Thaker of Washington University School of Medicine and the study chair of both OVATION 2 and OVATION 3 presented the phase II OVATION 2 survival results and the phase III design. Dr. Amir Jazaeri of MD Anderson Cancer Center, the lead principal investigator of our phase II MRD study, presented the preliminary clinical and translational findings.
Dr. William Bradley of the Medical College of Wisconsin, a principal investigator across OVATION 1, 2, and three, joined a pre-recorded conversation with a woman who was treated with IMNN-001 as a trial participant in OVATION 1 and who, nearly 10 years from her diagnosis, reported remaining free of recurrence. The last conversation is the one I keep returning to. Everything else we discussed today, enrollment rates, interim analyses, capital structure, it all exists to make that outcome available to more women. The replay of the event and the full presentation materials are available on the scientific presentations page of our website. If you have not already participated in the event, I highly recommend it. Turning to our lead phase III asset, we remain very encouraged by the continued pace of enrollment in our pivotal OVATION 3 study.
The trial continues to generate strong engagement from investigators and patients, reflecting the strength of data generated in OVATION 2, including a well-established safety profile and compelling overall survival and efficacy results that frankly we believe are unlike anything previously reported in this setting. At the R&D Day, we also put the operating plan on the record. We are targeting 50% enrollment in the first quarter of 2028 and completion of enrollment in the first quarter of 2029. The first pre-planned interim analysis, which is now aimed at the full intent-to-treat population versus the HRD-positive subgroup, will occur at 60% of the target overall survival events and is currently estimated for the first quarter of 2030. These timelines assume continued site activation and enrollment rates consistent with recent performance and remain subject to the usual variability of oncology trial execution. A word on how we are talking about enrollment.
Earlier in the trial, we reported that we were running above plan in essentially every month. Monthly enrollment in a trial of this kind goes up and down, and we do not want to set an expectation against any single month's rate. Therefore, we believe a better way to describe where we are is this: we are enrolling consistent with our plan, we are continuing to add sites, and we are seeing screening and randomization activity across the network of sites rather than concentrated at a handful of centers. We continue to make solid progress on site activation for the OVATION 3 trial. At the end of the quarter, we had 18 sites selected with nine active and nine in startup. We also have additional sites that have expressed interest that we are currently under evaluation. Our goal remains to have all planned sites activated by the end of 2027.
Patient enrollment is tracking consistently with our plan. Across active sites, average enrollment has been approximately 0.4 patients per site per month, which is above the planning assumption of approximately 0.3. We are encouraged by the early pace, and if we continue to activate sites in line with our plan and maintain strong enrollment productivity across the network, we expect to achieve our ultimate goal of completing patient enrollment by the first quarter of 2029. We remain focused on executing against both our site activation and enrollment timelines. During the quarter, we also entered into a cooperative research and development agreement, or CRADA, with the National Cancer Institute's Cancer Therapy Evaluation Program, which is often referred to as CTEP.
This agreement is designed to support the continued development of IMNN-001 and the work being conducted under the National Cancer Institute Experimental Therapeutics, or NExT, program, which is managed by CTEP, with CTEP assuming regulatory sponsorship. Through this agreement, National Cancer Institute investigators will evaluate IMNN-001 across additional solid tumor indications and combined regimens, leveraging the expertise and clinical trial infrastructure of the National Cancer Institute and the National Clinical Trials Network. Given IL-12's broad immunologic activity and the preclinical research we have conducted in-house, we believe IMNN-001 has potential beyond ovarian cancer and that it is meaningful. Importantly, Imunon will retain ownership of this background intellectual property and of new intellectual property solely generated by Imunon under the collaboration, including the right to use data generated under the collaboration for the research and development of IMNN-001, while National Cancer Institute assumes operational responsibility for conducting the studies.
What this all means is this provides a highly capital-efficient opportunity to expand the clinical trial evidence supporting IMNN-001 without diverting resources from our highest priority. Any additional studies conducted under the CRADA remain subject to National Cancer Institute resource allocation and prioritization and are not expected to impact our primary focus on OVATION 3. We will make sure of this. Our priority remains unchanged. Our capital, our team, our execution remain firmly focused on advancing OVATION 3 as rapidly as possible and in the most efficient way possible. The CRADA broadens the opportunity for IMNN-001 while allowing us to maintain our full commitment to completing the pivotal phase III trial in frontline ovarian cancer.
Before I hand over to Douglas to add some additional context around the NCI CRADA collaboration and broader operational updates, let me cover two additional corporate actions we have recently undertaken because they speak directly to that focus. Last month, we announced an agreement to sell our rights to ThermoDox, our heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, which intends to advance the asset in glioblastoma. This is consistent with the strategy we have described for some time. We want to find a committed development partner for ThermoDox rather than to carry it ourselves. As many of you will be familiar with, ThermoDox is a legacy asset that had been fully written off our balance sheet. So this transaction creates a path to future value from something currently carried at zero. Under the agreement, upon closing, Imunon would receive an equity interest of approximately 4.76% in VoxelDox.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
